← back to search

Yoko Kojima

University of Virginia · US
Area of research
Immunology · Virology
Research interest
Research focused on CD47 and Efferocytosis, with related work in Inflammation, Cell biology, Phagocytosis. Notable publications include 'CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis', 'A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer', and 'Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis'.
h-index
citations
1,374
works
12
NIH funding
primary concept
email

Recent publications

Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis
Nature Communications 2024cited by 26position: middledoi
Abstract 4147227: TET2-mediated Clonal Hematopoiesis Exacerbates Foam Cell Generation
Circulation 2024cited by 0position: middledoi
Abstract 128: Safety And Efficacy Of Pro-efferocytic Nanoparticles To Treat Atherosclerosis In A Porcine Model
Arteriosclerosis Thrombosis and Vascular Biology 2023cited by 0position: middledoi
Safety and Efficacy of Proefferocytic Nanoparticles to Treat Atherosclerosis in a Porcine Model
JVS Vascular Science 2023cited by 0position: middledoi
The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis
Nature Cardiovascular Research 2022cited by 54position: middledoi
Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade
Proceedings of the National Academy of Sciences 2020cited by 127position: middledoi
<sup>18</sup> F-Fluorodeoxyglucose-Positron Emission Tomography Imaging Detects Response to Therapeutic Intervention and Plaque Vulnerability in a Murine Model of Advanced Atherosclerotic Disease—Brief Report
Arteriosclerosis Thrombosis and Vascular Biology 2020cited by 16position: middledoi
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
Nature Communications 2017cited by 228position: middledoi
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Nature 2016cited by 649position: firstdoi
MicroRNA 139-5p coordinates APLNR-CXCR4 crosstalk during vascular maturation
Nature Communications 2016cited by 68position: middledoi
<i>CDKN2B</i> Regulates <i>TGF</i> β Signaling and Smooth Muscle Cell Investment of Hypoxic Neovessels
Circulation Research 2015cited by 58position: middledoi
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Journal of Clinical Investigation 2014cited by 148position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Lars Mäegdefessel · TUM Klinikum7 papers (2014–2023)Nicholas J. Leeper · Cardiovascular Institute of the South6 papers (2014–2022)Jianqin Ye · Stanford University6 papers (2015–2023)Lingfeng Luo · Palo Alto University4 papers (2022–2024)Bryan Ronain Smith · Charlottesville Medical Research4 papers (2020–2023)Shaunak Adkar · Palo Alto University3 papers (2023–2024)Nick J Leeper · Palo Alto University3 papers (2023–2024)Mozhgan Lotfi · Palo Alto University3 papers (2020–2024)Caitlin Bell · University of Colorado Anschutz Medical Campus3 papers (2023–2024)Ulf Hedin · Karolinska Institutet3 papers (2014–2016)Vivek Nanda · University of Alabama at Birmingham3 papers (2015–2020)Irving L. Weissman · Stanford University3 papers (2016–2022)Andrew J. Connolly · City College of San Francisco2 papers (2015–2016)Clint L. Miller · University of Virginia Health System2 papers (2014–2016)Yapei Zhang · Xi'an Jiaotong University2 papers (2023–2023)Kelly M. McKenna · California Institute for Regenerative Medicine2 papers (2016–2017)Daniel DiRenzo · University of Virginia2 papers (2015–2016) · 2 papers (2020–2022)Tom Alsaigh · University of California, San Diego2 papers (2023–2023)Kelly Downing · University of Virginia2 papers (2014–2015)